Core Insights - TIL (Tumor-Infiltrating Lymphocytes) therapy is recognized as a promising treatment for late-stage solid tumors, leveraging the patient's own tumor tissue for extraction and expansion [1][2] - The conventional TIL therapy faces challenges such as high costs, long preparation times, significant toxicity, and high clinical management thresholds [1] - Junshi Biosciences has made significant technological advancements with platforms like DeepTIL, NovaGMP, and RiverTIL, aimed at improving the efficiency and accessibility of TIL therapies [1][2][3] Group 1: Technological Innovations - The DeepTIL platform utilizes a non-nutritive cell culture process, significantly reducing production costs and eliminating reliance on high doses of IL-2, enhancing product safety and lowering implementation barriers [1] - The NovaGMP platform employs non-viral vector technology for gene-modified TIL products, improving efficacy while avoiding the high costs and complexities associated with viral vectors [1][2] - The RiverTIL platform aims for in vivo direct expansion of TILs, representing a shift from highly personalized to more standardized therapies, potentially lowering production costs and wait times for patients [2] Group 2: Product Development Strategy - The core product GC101 is the first natural TIL therapy that does not require intensive lymphodepleting chemotherapy or IL-2 administration, focusing on establishing new standards for safety and accessibility [2] - The product development strategy includes a tiered approach, with foundational products enhancing accessibility and advanced products like GC203 targeting efficacy improvements for challenging cancers such as pancreatic and ovarian cancer [2][3] - This strategy diversifies research risks and creates a clear pathway for market penetration and value capture, catering to various clinical scenarios and patient payment capabilities [2][3] Group 3: Operational and Commercial Considerations - Junshi Biosciences emphasizes a systematic approach to the entire industry chain, focusing on efficient technological breakthroughs and clinical advancements while maintaining the therapeutic potential of TIL therapy [3] - The innovative "time-segmented production process" allows for the pre-manufacturing and cryopreservation of TIL seed cells from surgically removed tumor tissues, enhancing flexibility and success rates in production [3] - The design of products considers hospital implementation convenience and health economic value, actively reducing reliance on scarce medical resources and shortening hospital stays, facilitating market access and negotiations with insurers [3]

Core Viewpoint - Junshi Biosciences has submitted its IPO application to the Hong Kong Stock Exchange, aiming to enter the biotech sector with its innovative TIL therapies, GC101 and GC203, which show promising clinical results in treating solid tumors [1] Company Overview - Junshi Biosciences, established six years ago, focuses on innovative cell therapies and drug development for solid tumors [1] - The company has reported cumulative losses exceeding 350 million yuan from 2023 to the first half of 2025, with cash and cash equivalents at 63.635 million yuan as of June 30, 2025 [1][5] Product Pipeline - GC101, a TIL therapy, has shown an objective response rate (ORR) of 41.7% in patients with metastatic non-small cell lung cancer and 30% in advanced melanoma patients, positioning it as a potential first TIL therapy approved in China [1][3] - GC203, the world's first non-viral vector gene-modified TIL therapy, has demonstrated a 33.3% ORR in heavily pre-treated ovarian cancer patients [4] Market Potential - The global TIL therapy market is expected to reach $4.5 billion by 2035, with China's market projected to grow at a compound annual growth rate (CAGR) of 40% from 2030 to 2035, outpacing global growth [4] Financial Challenges - The company has not yet generated product sales revenue and is experiencing increasing R&D expenditures, which reached 57.62 million yuan in 2023 and are projected to rise further [5] - Junshi Biosciences faces significant cash flow pressure due to ongoing losses and rising operational costs [5] Competitive Landscape - The TIL therapy market is highly competitive, with over ten similar therapies in development globally, including Iovance's approved product, Amtagvi [6] - Junshi Biosciences must continue to build advantages in clinical progress, efficacy data, and cost control to stand out in the competitive environment [6] Regulatory Environment - Positive signals from industry policies, such as breakthrough therapy designations and conditional approval processes, are accelerating the approval of innovative cell therapies in China [6]

Core Viewpoint - Junshi Biosciences has submitted its IPO application to the Hong Kong Stock Exchange, aiming to enter the biotech sector with its innovative TIL therapies, GC101 and GC203, which show promising clinical results in treating solid tumors [1][2]. Company Overview - Junshi Biosciences, established six years ago, focuses on innovative cell therapies and drug development for solid tumors [1]. - The company has developed GC101, the first TIL therapy that does not require high-intensity chemotherapy or IL-2 administration, and GC203, the first non-viral vector gene-modified TIL therapy [1][4]. Clinical Data - GC101 has shown an objective response rate (ORR) of 41.7% in patients with metastatic non-small cell lung cancer and 30% in patients with advanced melanoma [1][3]. - The therapy is currently undergoing critical clinical trials, with plans to submit a Biologics License Application (BLA) by 2026 [3]. Financial Performance - The company reported cumulative losses exceeding 350 million yuan from 2023 to mid-2025, with cash and cash equivalents at only 63.63 million yuan as of June 30, 2025 [1][5]. - R&D expenses have been increasing, with 57.62 million yuan in 2023, projected to rise to 90.99 million yuan in 2024 [5]. Market Potential - The global TIL therapy market is expected to reach $4.5 billion by 2035, with China's market projected to grow at a compound annual growth rate (CAGR) of 40% from 2030 to 2035 [4]. - Junshi's products are positioned to capitalize on this growth trend, especially with the anticipated lower treatment costs compared to imported therapies [3][4]. Competitive Landscape - The company faces competition from over ten similar TIL therapies currently in development, including IOVANCE's approved product in the U.S. [6]. - Junshi must continue to build advantages in clinical progress, efficacy data, and cost control to stand out in a rapidly evolving market [6]. Regulatory Environment - Positive signals from industry policies, such as breakthrough therapy designations and conditional approval processes, are expected to accelerate the approval of innovative cell therapies [6].

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Shanghai Juncell Therapeutics Co., Ltd.* 上海君賽生物股份有限公司 (the "Company") (A joint stock company incorporated in the Pe ...

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 Shanghai Juncell Therapeutics Co., Ltd.* 上海君賽生物股份有限公司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的要求 而刊發，僅用作提供資料予香港公眾人士。 Shanghai Juncell Therapeutics Co., Ltd.* 上海君賽生物股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即代表 閣 下知悉、接納並向本公司、本公司的獨家保薦人、整體協調人、顧問或包銷團成員表示同意： 倘於適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依據於香港公司註冊處處長登記的本公 司招股章程作出投資決定，招股章程的文本將於發售期內向公眾人 ...